Ciprofloxacin/celecoxib
| Combination of | |
|---|---|
Fluoroquinolone antibiotic | |
| Celecoxib | Cyclooxygenase-2 inhibitor |
| Clinical data | |
| Trade names | PrimeC |
| Legal status | |
| Legal status |
|
Ciprofloxacin/celecoxib or PrimeC is a fixed-dose combination of ciprofloxacin and celecoxib developed for ALS.[1][2]
References
- ^ Priyan, Vishnu (6 December 2023). "NeuroSense's trial of ALS drug meets primary and secondary endpoints". Clinical Trials Arena. Retrieved 7 December 2023.
- PMID 36106817.